Table 2. Presentation Features of... | American Society of Hematology

Table 2.

Presentation Features of Patients in MRC AML10

Parameter	Value	No. of Patients		Percent of Patients^*
		DAT	ADE

Age:	0-1	27	25	3
	2-14	116	118	13
	15-24	131	128	14
	25-34	147	149	16
	35-44	224	226	24
	45-55	280	278	30
	56+	4	4	<1
Sex:	Male	475	471	51
	Female	454	457	49
Type of AML:	De novo	863	859	93
	Secondary	66	69	7
White blood cell count: (×10⁹/L)	0-9	417	412	45
	10-99	366	385	40
	100-199	84	72	8
	200+	31	38	4
	Unknown	31	21	3
FAB type:	M0	16	12	2
	M1	136	172	17
	M2	254	253	27
	M3	143	130	15
	M4	184	184	20
	M5	79	81	9
	M6	28	24	3
	M7	24	18	2
	RAEB-t	13	17	2
	Bilineage	2	0	<1
	ALL	2	6	<1
	Unknown	48	31	4
Performance status:	Asymptomatic	250	245	27
	Minimal symptoms	485	489	52
	Ill	172	173	19
	Very ill	22	21	2
Cytogenetic group:	Favorable	156	165	17
	Intermediate	466	488	51
	Adverse	53	56	6
	Unknown	232	241	25

Parameter	Value	No. of Patients		Percent of Patients^*
		DAT	ADE

Age:	0-1	27	25	3
	2-14	116	118	13
	15-24	131	128	14
	25-34	147	149	16
	35-44	224	226	24
	45-55	280	278	30
	56+	4	4	<1
Sex:	Male	475	471	51
	Female	454	457	49
Type of AML:	De novo	863	859	93
	Secondary	66	69	7
White blood cell count: (×10⁹/L)	0-9	417	412	45
	10-99	366	385	40
	100-199	84	72	8
	200+	31	38	4
	Unknown	31	21	3
FAB type:	M0	16	12	2
	M1	136	172	17
	M2	254	253	27
	M3	143	130	15
	M4	184	184	20
	M5	79	81	9
	M6	28	24	3
	M7	24	18	2
	RAEB-t	13	17	2
	Bilineage	2	0	<1
	ALL	2	6	<1
	Unknown	48	31	4
Performance status:	Asymptomatic	250	245	27
	Minimal symptoms	485	489	52
	Ill	172	173	19
	Very ill	22	21	2
Cytogenetic group:	Favorable	156	165	17
	Intermediate	466	488	51
	Adverse	53	56	6
	Unknown	232	241	25

Percentages may not add to 100 because of rounding.